Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

Stopped early · Not applicable

Conditions studied: Coronary Artery Disease

In brief

This research study plans to evaluate the use of atorvastatin in patients with coronary artery disease given immediately before PCI and whether it will decrease the amount of heart damage after PCI.

Key facts

Study ID

NCT00979940

Run by

Indiana University

People needed

60

Starts

2008-11-01

Expected to finish

2014-08-01

Last updated by the study team

2015-09-22

Who can join

Age: 21 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients undergoing revascularization for significant coronary artery disease
• age range 21-85 years

You may not qualify if…

• non-STEMI, STEMI
• cancer
• renal failure with creatinine>3.0mg/dl
• liver cirrhosis
• lymphoproliferative disorder
• pregnancy
• thrombocytopenia<150'000
• coagulopathy (INR>1.5)
• abnormal liver function tests
• illicit drug use
• history of statin intolerance
• history of rhabdomyolysis
• planned use of Glycoprotein IIb/IIIa inhibitors during PCI
• current therapy with atorvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin

Where it is running

• Methodist Hospital — Indianapolis, Indiana, United States
• Wishard Hospital — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.